Trump Fast-Tracks Psychedelic Drug Research in Bid to Address Mental Health Crisis
Updated
Updated · Salon · Apr 22
Trump Fast-Tracks Psychedelic Drug Research in Bid to Address Mental Health Crisis
56 articles · Updated · Salon · Apr 22
President Donald Trump has signed an executive order to expedite federal review and research of psychedelic drugs, including ibogaine, for mental health treatment.
The order directs the FDA to accelerate approval processes and allocates $50 million for research, with a focus on therapies for veterans and treatment-resistant conditions.
While advocates welcome the move as historic, experts note the order may only modestly speed up drug approvals and emphasize the need for rigorous clinical trials.
The FDA just rejected MDMA. What changed to now accelerate psychedelic approvals?
Could this landmark order for medical psychedelics pave the way for recreational use?
Will fast-tracking approval actually lead to faster patient access or more bureaucratic delays?
What are the risks if these 'miracle' drugs fail to live up to the hype?
Is this executive order driven more by scientific promise or by celebrity influence?
How will patient safety be ensured for drugs like ibogaine with known fatal risks?